United Therapeutics Corporation Impairment of Long-Lived Assets Held-for-use
United Therapeutics Corporation (UTHR) reported Impairment of Long-Lived Assets Held-for-use of $21.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-02-25
- United Therapeutics Corporation impairment of long-lived assets held-for-use for the quarter ending 2025-12-31 was $0.00.
- United Therapeutics Corporation impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00.
- United Therapeutics Corporation impairment of long-lived assets held-for-use for the quarter ending 2024-12-31 was $0.00.
- United Therapeutics Corporation impairment of long-lived assets held-for-use for the quarter ending 2024-09-30 was $0.00.
- United Therapeutics Corporation impairment of long-lived assets held-for-use for fiscal 2025 was $21.70M.
- United Therapeutics Corporation impairment of long-lived assets held-for-use for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- United Therapeutics Corporation impairment of long-lived assets held-for-use for fiscal 2023 was $3.60M, a 67.86% decline from fiscal 2022.
- United Therapeutics Corporation impairment of long-lived assets held-for-use for fiscal 2022 was $11.20M, a 41.67% decline from fiscal 2021.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $21.70M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $21.70M 10-Q · filed 2025-10-29 | ||
| 2025-06-30 | $21.70M 10-Q · filed 2025-07-30 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $0.00 10-Q · filed 2025-10-29 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-07-30 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $3.60M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $3.60M 10-Q · filed 2024-10-30 | ||
| 2023-06-30 | $3.60M 10-Q · filed 2024-07-31 | |||
| 2022-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $11.20M derived: sum of 2 quarters · filed 2025-02-26 | $11.20M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $7.00M 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | |||
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $19.20M 10-K · filed 2024-02-21 | ||
| 2021-09-30 | $18.20M 10-Q · filed 2021-11-03 | |||
| 2021-03-31 | $17.00M 10-Q · filed 2021-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |